



## NEUROTHERA LABS

### **Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects**

December 30, 2025 - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“**Neurothera**” or the “**Company**”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), today announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues.

This patent grant in Israel joins previously granted patents for the same technology in Europe, Japan, Australia, and Canada, further strengthening the global intellectual property protection of Neurothera’s proprietary opioid-based platform.

The patented technology leverages N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms that amplify pain-relieving efficacy at lower doses.

This patent family is based on a pre-clinical study conducted to evaluate the nociceptive effect of PEA when combined with opiates such as oxycodone, in well-established, regulatory compliance, pre-clinical models.

In this study, researchers evaluated the pain relief potential of Neurothera’s proprietary drug combination of oxycodone and PEA versus standalone oxycodone in numerous concentrations.

Results showed that while oxycodone treatment led to marked alteration in animals' behavior and their response to pain stimuli, Neurothera's proprietary combination was found to exert beneficial effects like reduction or even preventing some of oxycodone drugs psychoactive adverse events. However, PEA was also able to potentiate therapeutic qualities of oxycodone, by prolonging the time the drug exerted its analgesic effects in all doses of oxycodone.

According to [The Business Research Company](#), oxycodone continues to have significant sales, with the global market size for oxycodone drugs valued at approximately \$5.5–\$5.7 billion in 2024. However, inherent risks in their use such as high susceptibility to misuse, potential addiction and diversion, severe psychological and physical dependence, and potential for fatal overdose, emphasize the critical need to find other effective and safe solutions at the same time.

The "opioid-sparing" effect shown in this study by Neurothera's proprietary combination may reduce the required opioid dosage, which may help mitigate side effects such as addiction and respiratory depression.

“We believe that granting a patent based on experiments that have shown such an outcome and validate the advantages of our proprietary opioids and N-acylethanolamines combination in maintaining immediate and strong pain relief effect without compromising patients’ safety is an important achievement of the Company,” said Oz Adler, Chief Executive Officer of Neurothera.

### **About Neurothera Labs Inc.**

Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

#### **For further information, please contact:**

Michal Efraty IR Manager

Neurothera Labs Inc.

Telephone: 972-3-7617108

Email: [michal@efraty.com](mailto:michal@efraty.com)

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

#### **Cautionary Note Regarding Forward-Looking Information**

*This press release contains “forward-looking statements” within the meaning of the securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will be issued as a result of a pending patent application or, if issued, whether it will be issued in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time at [sedarplus.ca](http://sedarplus.ca). Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third-party websites.*